Bipartisan Cancer Parity Drug Legislation Introduced in U.S. Congress
Two members of the House of Representatives have put political party differences aside and introduced bipartisan legislation that requires health insurers to cover traditional chemotherapy, along with oral medications associated with cancer treatment. U.S. Representatives Leonard Lance (R-NJ) and Brian Higgins (D-NY) have proposed the Cancer Drug Parity Act (H.R. 1409). The intent of the bill is to ensure appropriate oncologic treatments are affordable and covered for patients with cancer.
- Read more about Bipartisan Cancer Parity Drug Legislation Introduced in U.S. Congress
- 1 comment
- Add new comment
How One Institution Improved Accrual to Cancer Clinical Trials
One of the key factors to a cancer clinical trial’s success is the ability to enroll an adequate number of patients in an appropriate timeframe. Identifying barriers to slow accrual and ways to address them can help researchers and nurse scientists make big steps in the fight against cancer in the era of the National Cancer Moonshot Initiative.
The Case of the Omitted Opioid
Rocky is a 56-year-old man with stage III oropharyngeal cancer. He is undergoing concurrent chemotherapy and radiation. Rocky is a long-haul truck driver, has had sporadic medical care in the past, has no primary care provider, and usually visits the emergency department in whatever town he is in when he gets sick. He was diagnosed during one of those visits after an episode of hematemesis.
NIH Gets $2 Billion in Additional Funding; Senators Await CBO Score on AHCA; AHRQ Director Touts Importance of Nursing
In March 2017, President Trump issued what was called his “skinny budget.” The name refers to the short length of his proposed budget document, as well as the draconian cuts it brought to almost every federal agency.
- Read more about NIH Gets $2 Billion in Additional Funding; Senators Await CBO Score on AHCA; AHRQ Director Touts Importance of Nursing
- Add new comment
FDA Grants Accelerated Approval to Pembrolizumab in Combination With Pemetrexed and Carboplatin for Treatment of Metastatic Non-Squamous NSCLC
On May 10, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer.
- Read more about FDA Grants Accelerated Approval to Pembrolizumab in Combination With Pemetrexed and Carboplatin for Treatment of Metastatic Non-Squamous NSCLC
- Add new comment
Renew Your Mind, Body, and Spirit This May While Celebrating Nurses
This year the American Nurses Association’s National Nurses Week theme was Nursing: The Balance of Mind, Body, and Spirit. Take time this month to establish new ways to find balance. As nurses we are taught to view the individuals we care for holistically, yet we don’t always care for ourselves with the same focus. Spring is a symbolic time to renew. Take time to learn something new, take actions to renew your spirit, and be mindful of ways to nourish your body. These actions are important for your health and for the health or those you care for.
10% of Melanoma Survivors Report Intentional Tanning
A study published in Cancer Epidemiology, Biomarkers, and Prevention looking at the ultraviolet radiation exposure and sun protection behaviors among melanoma survivors found that many survivors have room for improvement.
FDA Grants Accelerated Approval to Avelumab for Urothelial Carcinoma
On May 9, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Nursing Considerations for Adverse Events From CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy offers options for pediatric patients with relapsed or refractory acute lymphoblastic leukemia, but it comes with a unique set of side effects that can range from mild to severe. As the primary patient providers, oncology nurses are often the first to identify signs and symptoms of adverse events and acute changes in patients’ status. Understanding what to watch for can improve outcomes and help nurses deliver safe, effective care.
Research Gives Insight on Cognitive Function in Patients With Cancer
Poor cognitive function can cause distress, impact quality of life, and contribute to treatment non-adherence, Catherine Bender, PhD, RN, FAAN, from the University of Pittsburgh, explained during the Distinguished Nurse Researcher session at the 42nd Annual Congress in Denver, CO. She is the 2017 recipient of the Distinguished Nurse Research Award, which recognizes the contributions of a member who has conducted or promoted research that has enhanced the science and practice of oncology nursing.